Espresso Coffee for the Treatment of Somnolence in Parkinson’s Disease: Results of n-of-1 Trials by Joaquim J. Ferreira et al.
March 2016 | Volume 7 | Article 271
Original research
published: 08 March 2016
doi: 10.3389/fneur.2016.00027
Frontiers in Neurology | www.frontiersin.org
Edited by: 
Jaime Kulisevsky, 
Sant Pau Institute of Biomedical 
Research, Spain
Reviewed by: 
Manuel Menéndez-González, 
Hospital Universitario Central de 
Asturias, Spain 
Juan Carlos Martinez Castrillo, 
Hospital Ramon y Cajal, Spain
*Correspondence:
Joaquim J. Ferreira  
joaquimjferreira@gmail.com
Specialty section: 
This article was submitted to 
Movement Disorders, 
a section of the journal 
Frontiers in Neurology
Received: 30 October 2015
Accepted: 22 February 2016
Published: 08 March 2016
Citation: 
Ferreira JJ, Mestre T, Guedes LC, 
Coelho M, Rosa MM, Santos AT, 
Barra M, Sampaio C and Rascol O 
(2016) Espresso Coffee for the 
Treatment of Somnolence in 
Parkinson’s Disease: Results of 
n-of-1 Trials. 
Front. Neurol. 7:27. 
doi: 10.3389/fneur.2016.00027
espresso coffee for the Treatment of 
somnolence in Parkinson’s Disease: 
results of n-of-1 Trials
Joaquim J. Ferreira1,2* , Tiago Mestre1 , Leonor Correia Guedes1 , Miguel Coelho1 ,  
Mário M. Rosa1,2 , Ana T. Santos1 , Márcio Barra1 , Cristina Sampaio1,2 and Olivier Rascol3
1 Clinical Pharmacology Unit, Faculty of Medicine, Instituto de Medicina Molecular, University of Lisbon, Lisbon, Portugal, 
2 Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Lisbon, Portugal, 
3 Departments of Clinical Pharmacology and Neurosciences, University Hospital of Toulouse and Clinical Investigation Center 
INSERM CIC9302 and UMR825, University of Toulouse III, Toulouse, France
There is limited information available concerning the treatment of daytime somnolence 
associated with Parkinson’s disease (PD); the most frequently applied therapeutic 
strategies include decreasing the dose of dopamine agonists or adding potential 
wake-promoting agents. There is recent data from a placebo-controlled trial conclud-
ing on a non-significant trend in favor of caffeine. We aimed to evaluate the efficacy of 
espresso-coffee in the treatment of daytime somnolence in PD. To evaluate the efficacy 
of espresso-coffee in the treatment of daytime somnolence in PD, we have conducted 
multiple single-patient (n-of-1) clinical trials comparing regular espresso coffee to 
decaffeinated coffee in PD patients presenting moderate to severe daytime somnolence 
defined as an Epworth Sleepiness Scale score >9. Each single-patient (n-of-1) trial 
included a sequence of three crossovers (two treatment periods separated by two days 
of washout). Four patients were included in the studies and three completed the three 
pairs of treatment periods. In two of the four patients, espresso coffee was considered 
beneficial. This study concludes that multiple single patient trials are feasible in PD and 
suggests that espresso-coffee may have a beneficial effect on daytime somnolence in 
some patients. These results cannot be generalized beyond the patients included in 
these trials.
Keywords: Parkinson’s disease, daytime sleepiness, caffeine, n-of-1 trials, sleep
inTrODUcTiOn
Daytime somnolence is a frequent problem in Parkinson’s disease (PD). (1). Clinical and epide-
miological data suggest that many factors may disturb sleep quality and/or induce sedation in PD 
patients. Some may be related to the disease itself (nighttime motor, psychiatric handicap, or pain) or 
to comorbidity (depression) or aging. Moreover, these may also be linked to direct or indirect effects 
Abbreviations: EDS, excessive daytime somnolence; EFNS/MDS-ES, European Federation of Neurological Societies/
Movement Disorder Society – European Section; ESS, Epworth Sleepiness Scale; HY, Hoehn and Yahr; PD, Parkinson’s disease; 
MMSE, mini-mental state examination; RCT, randomized clinical trial; UPDRS, unified Parkinson’s Disease Rating Scale; VAS, 
Visual Analog scale; SE, Schwab and England.
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of the drugs prescribed to these patients, such as antiparkinsonian 
dopaminergic drugs, and non-antiparkinsonian comedications 
that affect sleep mechanisms (antidepressants, hypnotics, antip-
sychotics, antihypertensives, etc.). The respective role of all these 
contributing factors may also vary from one patient to another, 
and it is often difficult to assess and conclude whether the effects 
of a given drug on sleep or alertness results from a direct or an 
indirect mechanism involving one or several of these factors. 
Although it represents a relevant problem for the management 
of PD patients, no treatment intervention other than the control 
of the precipitating factors has shown a clear benefit. Recently, 
an European Federation of Neurological Societies/Movement 
Disorder Society – European Section (EFNS/MDS-ES) therapeutic 
review suggested Good Practice Points advice to reduce daytime 
somnolence either by decreasing the dose of dopaminergic drugs, 
switching to other dopamine agonists, or by adding wake-pro-
moting agents like methylphenidate (2, 3). Despite this, the only 
Level B recommendation is to add Modafinil, which is the only 
pharmacological intervention that has been specifically studied 
for the treatment of excessive daytime somnolence (EDS) in PD 
patients (4–9). A recent placebo-controlled trial reported a non-
significant trend for caffeine, up to 200 mg BID, to improve exces-
sive daytime sleepiness in patients with PD (10). Furthermore, no 
other potential psychostimulant drugs (selegiline, amphetamines, 
methylphenidate) or any other non-pharmacological treatments 
have yet been properly evaluated for their ability to treat daytime 
somnolence in PD patients.
Therefore, to approach this problem, we designed multiple 
single patient trials to find out if espresso-coffee has any benefit 
in daytime sleepiness in PD patients.
MaTerials anD MeThODs
study Design and Patients
This was a series of multiple crossover clinical trials performed 
in one site (Lisbon, Portugal) with a run-in period of 1–2 weeks 
and a planned duration of 10  weeks. The study included four 
single-patient (n-of-1) trials, which were randomized, placebo-
controlled, double-blind, and multi-crossover, which were 
designed to evaluate the efficacy, tolerability, and safety of regular 
espresso coffee compared to decaffeinated coffee in PD subjects 
with EDS. A secondary objective was to assess the usefulness and 
applicability of clinical trials with a single-patient design to evalu-
ate the efficacy of therapeutic interventions in PD.
Parkinson’s disease patients presenting moderate to severe 
daytime somnolence were selected from the movement disorders 
outpatient clinic of the Lisbon University Hospital. Patients were 
considered eligible if they fulfilled the following criteria: diagno-
sis of idiopathic PD according to the UK Brain Bank (11), aged 
30 years or above, have a modified Hoehn and Yahr stage <5 in 
the “OFF” state, been on a stable dose of all antiparkinsonian drug 
treatments for at least 1 month, and have a daytime somnolence 
defined as an Epworth Sleepiness Score higher than 9 (4). Non-
eligibility criteria were: intake of antidepressants or anxiolytics 
that had not been provided at a stable dose for at least 1 month 
(dose had to remain stable during the study); relevant medical 
diseases, malignancy or other progressive neurological disorder; 
clinically significant or unstable arterial hypertension or ECG 
abnormalities; cognitive impairment as defined by mini-mental 
state examination (MMSE) score ≤24; clinically significant psy-
chiatric illness, including previous hallucinations or psychotic 
symptoms; history of alcohol or coffee abuse (more than six cups 
daily) or other substance abuse within the past 2 years; patients 
with migraine or other headache types related to the consump-
tion of coffee; and patients who were unlikely to comply with a 
coffee intake suspension.
The study was approved by the Ethics Committee Board of The 
Faculty of Medicine, University of Lisbon, and all participants 
gave written informed consent.
Procedures
Each crossover lasted 2 weeks and was composed of two treatment 
periods preceded and separated by 2 days of washout (Figure 1). 
Each treatment period corresponded to 5  days of treatment A 
or B (A – regular coffee, B – decaffeinated coffee). The order of 
the two treatment periods within each pair was randomized. 
Following a screening visit to ensure that subjects met all enroll-
ment criteria, subjects started a regular coffee run-in period of 
1  week. During this run-in period, subjects took two to four 
regular espresso coffees daily. Eligible subjects, who maintained 
a stable consumption of coffee without relevant adverse effects 
during the run-in period for at least 4 days, were randomized to 
a multi-crossover sequence. Follow-up visits were planned with 
7-day intervals. During the preliminary single-blinded run-in 
period, the patient was not aware whether he or she was receiving 
coffee with or without caffeine. If intolerable side effects occurred, 
the dose of caffeine was titrated to a minimum of two cups a day. 
If the adverse effects persisted with this lower dose, the patient 
was dropped from the study.
Each patient received a capsule coffee machine for the purpose 
of the study. An independent pharmacist was responsible for 
preparing the randomization schedule by using randomization-
generating software.
To reduce the influence of a change of treatment and the pos-
sibility that the patient would know the duration and day of onset 
of each treatment, the patient took the placebo (decaffeinated 
coffee) during the washout days (Figure 1).
Outcomes
According to the suggested applications in n-of-1 clinical trials 
(12), the primary efficacy outcome was a 7-point Likert scale 
monitoring subjective “daytime somnolence”. This questionnaire 
was completed by the patients on day 5 of each new treatment 
period and referred to the clinical state during the previous week. 
Secondary efficacy endpoints were: a 7-point scale monitoring 
subjective “tendency to sleep” episodes, a 7-point scale moni-
toring daytime somnolence in the situation/activity in which 
patients presented the highest tendency to fall asleep, a visual 
analog scale (VAS) of fatigue, and the Epworth Sleepiness Scale 
(ESS) (13).
Safety outcomes were: reporting of adverse events, Unified 
Parkinson’s Disease Rating Scale (UPDRS) Part III (motor) 
FigUre 1 | study design.
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during “ON” state, and UPDRS Part II (Activities of Daily Living, 
ADL) during “ON” state.
investigational Therapy
The therapy under investigation was regular espresso coffee 
(in espresso machine capsules) as a pragmatic way of deliver-
ing caffeine. It was administered as cups of espresso coffee and 
decaffeinated espresso coffee was given as the “placebo therapy.” 
The oral cups of espresso coffee were administered two to four 
times a day. Each cup of regular espresso coffee corresponded to 
100 mg caffeine (trademark Platina Coffee, Delta), while a cup of 
decaffeinated coffee corresponded to 2  mg caffeine (trademark 
Novadelta Light, Delta). The coffee was packed in unidentified 
capsules for espresso machines.
statistica5l Methods
The first approach to analyze the results was to simply plot the 
data and examine the results visually, graphically adjusting the 
randomized sequence of treatments to a rigid sequence of coffee 
followed by decaffeinated coffee.
For the primary analysis of efficacy on an individual patient, we 
applied the methodology suggested by Guyatt and coworkers (12). 
We followed the recommendation that, when analyzing outcomes 
using a 7-point Likert scale, one should first calculate the difference 
(“espresso coffee” – “decaffeinated coffee”) for each crossover and 
afterward calculate the mean difference from the different pairs 
of treatment periods (D). Guyatt et al. proposed that, according to 
their experience with symptom questionnaires that used a 7-point 
scale, an improvement of 0.5 points per question corresponded to a 
noticeable change in the patient’s well-being. As our trial included 
three questions evaluated with 7-point scales, a total change of 
1.5 or higher was considered clinically important. Guyatt et al. 
also proposed a set of statistical criteria to classify individual n-
of-1 trials, using a combination of the clinical importance cut-off 
(0.5 points per question mean difference in symptoms score) 
and statistical evaluation of the difference observed (one-tailed 
“p” < 0.05). n-of-1 trials were classified as beneficial (definitive 
answer) if “D” ≥ 0.5 and “p” ≤ 0.05; as tending toward beneficial 
if 0.5 ≥ “D” ≥ 0.3 and “p” ≤ 0.05 and CI includes 0.5 or “D” ≥ 0.5 
and “p” > 0.05; as neutral if 0.25 > “D” > −0.25, “p” > 0.05 and 
CI <  0.5 or 0.25 >  “D” > −0.25, “p” >  0.05 and “D” for each 
pair ≤ 0.5 (12).
In addition, a paired student t-test was also applied as a global 
analysis (12, 14, 15). For each crossover sequence, we obtained 
a single score for each pair by subtracting the mean score of the 
caffeine period from the mean score of the decaffeinated period. 
These different scores constituted the data for the paired t, and 
the number of degrees of freedom was set as the number of 
pairs minus 1. Statistical software programs (SPSS) were used to 
calculate the p value. Each test performed was a one-sided test 
at a 5% level of significance. The limitations of this test were the 
assumption of a normal distribution of the data and independ-
ence of data from treatment periods. We accepted 80% confidence 
intervals regarding treatment effects within these n-of-1 trials as 
a compromise between the inherently low power of n-of-1 trials 
having four or fewer treatment pairs and the need to avoid type I 
(false positive) errors.
Using the same methodology as other researchers, we also 
defined responders and non-responders according to the num-
ber of pairs in which a clear difference between treatments was 
seen (16, 17). We categorized patients into “responder” (more 
favorable response to caffeine on the measure by any quantity in 
all three treatment pairs), “possible responder,” (in two of three 
treatment pairs), or “non-responder.”
resUlTs
Four patients were included in the study (Table  1), and three 
patients completed the three pairs of treatment periods. One 
patient did not complete the third crossover due to logistical diffi-
culties in performing the last study visits, and only two crossovers 
were included in the analysis.
The recruited patients presented baseline staging Hoehn and 
Yahr scores between 1.5 and 2.5 and ESS scores ranging from 11 
to 20. Other patient demographic and clinical characteristics are 
described in Table 1.
During the run-in phase, in three patients, treatment was 
adjusted to three cups of coffee per day, and one patient was 
up-titrated to four cups daily. All four patients entered the rand-
omization phase.
TaBle 1 | Patient characteristics at screening visit.
Patient 
identification
gender age 
(years)
Disease 
duration 
(years)
Motor 
fluctuations
Working 
status
Driving PD medication 
(daily)
UPDrs  
i
UPDrs  
ii On
UPDrs  
iii On
hY se ess
Patient 1 Male 56 5 Yes Active Yes Selegiline 10 mg; 
Pergolide 2 mg
3 12 30 2 90 19
Patient 2 Male 47 1 No Active Yes Levodopa 150 mg 1 1 13 2.5 100 20
Patient 3 Male 66 10 Yes Active Yes Levodopa 
1000 mg
1 18 19 2 70 11
Selegiline 10 mg
Bromocriptine 
12.5 mg
Patient 4 Male 75 6 No Retired No Levodopa 500 mg 6 15 14 1.5 75 13
Selegiline 10 mg
Amantadine 
100 mg
Ropinirole 6 mg
UPDRS: Unified Parkinson’s Disease Rating Scale; HY: Hoehn and Yahr; SE: Schwab and England; ESS: Epworth Sleepiness Scale.
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to continue the coffee intake. During the study there was one 
drop-out not related to an adverse effect, one patient suffered an 
episode of sleep attack during a period of decaffeinated coffee 
intake, and one case of each of the following was reported: head-
ache, tremor aggravation, and insomnia during an espresso coffee 
intake period. In addition, an episode of insomnia between the 
screening visit and V0, when no study treatment was being taken, 
was reported. There were neither reports of serious adverse drug 
reactions nor cases of hypertension or parkinsonism aggravation, 
and the objective evaluation of the UPDRS did not detect any 
parkinsonism aggravation.
DiscUssiOn
This study is the first to investigate the efficacy of espresso coffee 
in the treatment of daytime somnolence in PD, using multiple 
single-patient (n-of 1) clinical trials. We compared the effects 
of regular espresso coffee to decaffeinated coffee and identified 
that in two of the four patients studied, espresso coffee was a 
beneficial therapeutic intervention for EDS. In the other two 
patients studied, the effect was inconclusive, due in one case it 
only being possible to complete two crossovers, which limited 
the power of that study. Insomnia and tremor were identified 
as potential adverse events that should be of special interest in 
clinical practice or when planning further studies (18).
This study is the second (19) to report on a set of n-of-1 trials 
conducted in PD patients, reinforcing that it is feasible to conduct 
this type of trial in the PD population. As anticipated, it was not 
possible to obtain a mean estimate of effect or a precise estimation 
of frequency of responders, but data concerning the magnitude 
of effect to expect, variability of outcomes, and the definition of 
responder can be learnt from our study. A previous multiple-
cross-over n-of-1 proof-of-concept study was able to conclude 
on the potential antiparkinsonian and antidyskinetic effect of 
naftazone (19). In the field of movement disorders, a n-of-1 type 
of study design was also applied to evaluate the efficacy of two 
deep brain stimulation targets in a patient with a severe form of 
Tourette’s syndrome (20).
The visual analysis of the plotted results of the 7-point scales 
immediately allowed us to distinguish the pattern of response in 
two patients (patients 1 and 4). They presented a pattern where, 
within each pair of treatment periods (crossover), they gave higher 
scores during the regular espresso coffee intake as compared with 
the alternative treatment in the same crossover. This generates 
a saw-tooth-like pattern of response, which is suggestive of a 
beneficial effect. This pattern is visible for the outcomes of global 
daytime somnolence and somnolence during specific tasks with 
higher tendency for somnolence, but it was not observed for the 
outcome evaluating the risk of falling asleep (Table 2).
When using the simplest criteria suggested by Guyatt to 
analyze the benefit of an intervention for a single patient, we con-
cluded that for the primary outcome, the therapeutic intervention 
was classified as having a “beneficial trend” in two patients. The 
magnitude of the effect obtained by the combination of the results 
generated with the three 7-point scales was judged as clinically 
important in the same two patients (Tables 2 and 3). The same 
patients were classified as possible responders using other clas-
sifications based on the number of paired periods favorable to the 
active intervention. More favorable and conclusive results were 
obtained when we analyzed the outcome of daytime somnolence 
during the activity/tasks that generated higher somnolence 
(Table 2). In this case, for patient 1, the benefit of espresso coffee 
reached a statistically significant result with a one-tailed paired 
t-test analysis (p = 0.03).
When calculating the 80% CI of the estimated difference of 
the 7-point scale outcome for each single patient, it was favorable 
toward espresso coffee and excluded zero in patients 1 and 4 for 
the outcomes of global daytime somnolence and somnolence 
during a specific task.
When using the ESS scale, no trend was captured (Table 4); 
however, the evaluation of fatigue using a VAS also suggested a 
beneficial effect of espresso coffee in patient 1.
After study termination, the two patients with positive results 
felt that taking espresso coffee was beneficial and stayed on the 
same medication. Interestingly, the patient with only two crosso-
vers to analyze and inconclusive results also thought it beneficial 
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Current therapy evaluations recommends the use of rand-
omized controlled trials (RCT’s), which are designed to average 
the effect of treatments across a group of individuals. This was the 
type of design applied in a recently published trial conducted by 
RB Postuma and colleagues assessing the effects of caffeine (up to 
200 mg BID) upon daytime somnolence (10). In a 6-week ran-
domized placebo-controlled trial, they found a non-significant 
reduction in ESS score (significant on per-protocol analysis) and 
an improvement of somnolence on a Clinical Global Impression 
of Change scale. Although concluding on a trend for an improve-
ment on daytime somnolence favoring caffeine, this study design 
did not allow the investigators to identify the individual responses 
or to determine the extent to which an average effect would apply 
to an individual patient.
Another main question at an early stage of the development of 
a new therapy is the determination whether there is any beneficial 
effect of a specific intervention. The efficacy of a novel therapeutic 
intervention in PD is usually assessed by performing a standard 
parallel or a crossover trial to evaluate, which demand large 
studies with great logistical effort and expense. An alternative 
approach is to verify the existence of responders independently 
of their frequency, and one of the clinical trial designs that can be 
used is the single subject research study (21).
A single-patient n-of-1 randomized clinical trial involves 
the analysis of the response of one subject when given two or 
more treatments over time, based on a randomization scheme 
(12). PD seems an appropriate disease for the application of this 
methodology because it is a slowly progressive chronic disease, 
and if a treatment proves effective, maintenance therapy is likely 
to be prolonged. This study has shown that n-of-1 clinical trials 
are able to evaluate pharmacological therapeutic interventions 
in PD and that the incorporation of blinding and randomization 
is also possible. We have also demonstrated that it is possible 
to identify responders making this type of study a potential 
alternative to larger pilot exploratory studies when the objective 
is to evaluate whether responders exist, independent of the mag-
nitude of effect. Additionally, there is only a minimal need for 
infrastructural support, namely placebo production and design 
implementation.
There are, however, weaknesses with this type of trial. n-of-1 
trials are designed to evaluate individual effects to assess the 
origins of the variation in type of response instead of estimate the 
average effect in a population. For this reason, results are analyzed 
for each patient separately, but the methodology for statistical 
testing in single-patient trials is limited (22). In our study, for 
pragmatic reasons, the number of treatment periods was set as 
three, which constitutes the minimum recommended number of 
crossovers for this type of trial (12). The 7-point Likert scales, 
used here, are well placed to capture an effect in multi-crossover 
studies, as outcomes designed for a specific patient-related prob-
lem may be more sensitive to change in these designs. With all 
the limitations of conducting formal statistical analysis in these 
studies, the statistical relevance of an effect was shown when 
applied to a question regarding a specific patient situation (e.g., 
when the tendency to feel somnolent was higher) and not in ques-
tions that were global or non-patient specific. It is worth noting 
that the multiple crossover design may facilitate the occurrence 
TaBle 3 | combination of the results of the 7-point scale questions.
Daytime somnolence somnolence during tasks Fall asleep Pooled guyatt criteria
Patient 1 +1.3 +1.3 0 2.6 Clinical important result
Patient 2 −0.3 0.3 0 0
Patient 3 0 −1 −1 −2
Patient 4 +1.3 +1.3 1 3.6 Clinical important result
TaBle 4 | results of epworth sleepiness scale and Visual analogic scale for fatigue.
Pair 1 Pair 2 Pair 3
coffee Placebo coffee Placebo coffee Placebo Mean  
coffee
Mean  
placebo
Paired t-test one  
tailed
no. pairs  
favoring coffee
ESS Patient 1 16 15 14 20 14 16 14.7 17.0 0.18 2
Patient 2 6 5 6 6 13 15 8.3 8.7 0.37 1
Patient 3 9 4 9 6 5 Na 9.0 5.0 0.08 0
Patient 4 13 16 11 7 15 15 13.0 12.7 0.44 1
Fatigue 
VAS
Patient 1 23 33 23 49 34 49 26.7 43.7 0.03 3
Patient 2 33 32 7 25 40 38 26.7 31.7 0.26 1
Patient 3 91 96 6 92 94 Na 48.5 94.0 0.23 2
Patient 4 71 46 43 29 15 22 43.0 32.3 0.19 1
March 2016 | Volume 7 | Article 276
Ferreira et al. Coffee for Sleepiness in Parkinson’s Disease
Frontiers in Neurology | www.frontiersin.org
of a rebound effect due to caffeine withdrawal that could favor the 
caffeine intervention.
Another limitation of this study was the fact that the decaffein-
ated capsules were not a truly inert intervention, seeing as each 
capsule contained approximately 2 mg of caffeine.
Our study did not address also the question of the usefulness 
of conducting n-of-1 studies as compared with the use of these 
interventions during regular care, and two randomized trials 
that have done such a comparison have had divergent results 
(23, 24). A further limitation of this trial was the small number 
of patients evaluated and the limited number of evaluations per 
treatment period. As a consequence, a definitive result has not 
been obtained. Our study has concluded that n-of-1 trials are 
feasible in PD. It also showed that espresso coffee has a beneficial 
effect on daytime somnolence in some patients. However, this 
study design does not allow results to be generalized beyond the 
patients included in these trials.
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